Back to results
US 2023/0407307 A1Published application
Modified antisense oligonucleotides targeting splicing factors
AssigneeThe Jackson Laboratory
InventorsOlga Anczuków-Camarda, Nathan Leclair
Life of this patent
Estimating the term…
Abstract
Provided herein are chemically modified antisense oligonucleotides that bind to sequences on mRNAs encoding the splicing factor TKA2β, associated with cancer.
Claims32
An antisense oligonucleotide comprising a sequence that binds to a target sequence on an mRNA that encodes TRA2β, wherein the antisense oligonucleotide further comprises a 2′-O-methoxyethyl modification.
Dependencies are inferred from the claim text.